3SBIO (01530.HK) stock is soaring 5.19% in pre-market trading on Wednesday, following the company's announcement of robust financial results for the fiscal year and a final dividend declaration.
The Chinese biopharmaceutical company reported impressive financial metrics, including revenue of RMB 9,108 million and a gross profit of RMB 7,828.4 million. The company maintained a high gross margin of 86%, demonstrating strong operational efficiency. 3SBIO's EBITDA reached RMB 3,173.8 million, with adjusted EBITDA slightly higher at RMB 3,402.3 million. The company also posted a basic earnings per share (EPS) of RMB 0.86.
Investors are particularly encouraged by 3SBIO's announcement of a final dividend of HKD25 cents per share, signaling confidence in the company's financial health and commitment to shareholder returns. This combination of strong financial performance and generous dividend payout appears to be driving the significant pre-market surge in 3SBIO's stock price.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.